Product Details
| Product Name:
MT 63-78 |
CAS No.:
1179347-65-9 |
| Purity:
97.11% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | MT 63-78 |
| Description | MT 63-78 is a specific and effective direct AMPK activator (EC50: 25 μM) that blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. It has antitumor effects and induces cell mitotic arrest and apoptosis. |
| In vitro | MT 63-78 (0-50 μM; 24 hours; LNCaP, PC3, C4-4, C4-2B, CL1 and 22RV1 cells) treatment induces a reduction of anti-apoptotic Mcl-1 and an accumulation of the pro-apoptotic BH3-only protein Puma. MT 63-78 (0-50 μM; 4 days; LNCaP and PC3 cells) treatment displays a dose-dependent decrease in cell number and activation of AMPK signaling. MT 63-78 (0-50 μM; 30 minutes; LNCaP and PC3 cells) treatment shows dose-dependent phosphorylation of AMPK targets Acetyl-CoA Carboxylase (ACC) on Ser79 and Raptor on Ser792, and increases Thr172 phosphorylation on the AMPK α subunit. MT 63-78 (25 μM; 24 hours; LNCaP and CRPC cells) treatment causes significant enrichment in the G2/M population. |
| In vivo | MT 63-78 (30 mg/kg; intraperitoneal injection; daily; for 14 days; C57 BL/6 male mice) treatment results in a 33% inhibition of tumor growth. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 3.26 mg/mL (10 mM)
|
| Keywords | Raptor | mitotic | Mammalian target of Rapamycin | direct | antitumor | mTOR | MT 63-78 | Thr172 | arrest | dephosphorylation | Inhibitor | AMP-activated protein kinase | Mcl-1 | mTORC1 | Apoptosis | AMPK | MT 63 78 | lipogenesis | BH3 | MT 6378 | p53 | inhibit |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Metformin hydrochloride | Chitosan oligosaccharide |
| Related Compound Libraries | Bioactive Compound Library | Antidepressant Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Neuroprotective Compound Library | Stem Cell Differentiation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:931596-95-1
$30.00 / 5mg
-
CAS:2327925-35-7
$58.00 / 1mg
-
CAS:2231744-29-7
$88.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$3100.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
|
|
$5.00/1BOX |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2024-12-24 |
|
|
$30.00/1Box |
|
Hebei Weimiao Import and Export Trade Co., Ltd.
|
2024-11-21 |
United States